

From science to start-up

Researchers meet Innovators, TU Berlin, MCAA Jule 11, 2019

> Francesco Gatto, PhD Chief Scientific Officer gatto@elypta.com www.elypta.com


IMPRECISION MEDICINE

Esomepraziole Heartburn 1 in 25


Rosuvastatin High cholesterol 1 in 20

Fluticasone propionate Ashtma 1 in 20

PRECISION MEDICINE MUST GATHER AND INTEGRATE DATA FROM ALL RELEVANT OMICS TO BE EFFECTIVE – A SYSTEMS BIOLOGY EFFORT




ELYPTA IDENTIFIED A CRITICAL PROCESS IN METABOLISM THAT PROVIDE DATA USEFUL TOWARDS CANCER DIAGNOSTICS




Gatto et al. (2014) "Chromosome 3p loss of heterozygosity is associated with a unique metabolic network in clear cell renal carcinoma" PNAS Gatto et al. (2016) "Glycosaminoglycan Profiling in Patients' Plasma and Urine Predicts the Occurrence of Metastatic Clear Cell Renal Cell Carcinoma." Cell Reports


HARNESSING DEREGULATION OF RENAL CELL CARCINOMA (RCC) GLYCOSAMINOGLYCANS (GAG) METABOLISM FOR DIAGNOSIS




Gatto et al. (2016) "Glycosaminoglycan Profiling in Patients' Plasma and Urine Predicts the Occurrence of Metastatic Clear Cell Renal Cell Carcinoma." Cell Reports Gatto et al. (2018), "Plasma glycosaminoglycans as diagnostic and prognostic biomarkers in surgically treated renal cell carcinoma" Eur. Uro. Oncology






































WHY YOU?




CHANGING THE WORLD EQUATES A LASTING AND MEANINGFUL IMPACT ON HUMAN LIFE






THESE VENTURES START BY *FIRST* IDENTIFYING A NEED / PROBLEM, THEN FORMULATING AN IDEA AND NEXT FINDING A SOLUTION






IDEAS CAN DERIVE FROM CUNNING EXPLOITATION OF EXISTING KNOWLEDGE....






IDEAS CAN DERIVE FROM CUNNING EXPLOITATION OF EXISTING KNOWLEDGE... OR NEW KNOWLEDGE






THIS CONCEPT DEPENDS ON SCIENTIFIC DISCOVERIES




CHANGING THE WORLD IS RARELY COST-NEUTRAL THIS SHOULD BE THE ONLY REASON WE SELL SCIENCE

ELYPTA






FROM SCIENCE TO BUSINESS: THE PERSPECTIVE SWITCH AND MONEY CENTRALITY







THIS LONG-TERM REASONING HOLDS IF YOU HAVE GUARANTEED RETURNS: IP CENTRALITY















HOW DID WE END UP HERE? THIS IS HOW WE STARTED





SO LET US NOT FORGET WHY ONLY SCIENTISTS CAN CHANGE THE WORLD





Thank you for your attention!

Francesco Gatto gatto@elypta.com